Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Sollers opened a product development center in Kazan

8/25/23 SVAV

Sales of M.Video stores in the new compact format are 15% higher than planned

8/25/23 MVID

M.video reported for 6 6 months of 2023 by IFRS

8/25/23 MVID

Sollers will launch car production in Azerbaijan in the fall

8/25/23 SVAV

The NetEase announced a quarterly dividend

8/24/23 NTES

Nizhnekamskneftekhim reported for 6 months of 2023 by RAS

8/24/23 NKNC

Sollers plans to sell at least 10 thousand Atlant and Argo in 2023

8/24/23 SVAV

Kazanorgsintez reported for 6 months of 2023 by RAS

8/24/23 KZOS

TGC-14 reported for 6 months of 2023 by IFRS

8/24/23 TGKN

Sollers launched a full cycle of production of the Atlant van

8/24/23 SVAV